Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > BUSINESS
BUSINESS
- Nippon Shinyaku Plans Generic Launch to Complement Its New Drug Lineup in Priority Field
September 6, 2012
- AZ Aims to Become Market Leader with Symbicort on Additional Indication for COPD
September 6, 2012
- DSP Submits Imported Drug Registration Application in China for Anticancer Agent Calsed
September 6, 2012
- Meiji Seika Pharma Aims to Bolster Presence with COPD Drug Oxis
September 5, 2012
- Flu Vaccine Deal with BIKEN Hoped to Yield Synergies in Elderly Products: MSD Pres. Alvarez
September 5, 2012
- Anticancer Agent Enzalutamide Approved in the US: Astellas
September 5, 2012
- Halaven Approved in South Korea, To Be Launched in Jan. 2013: Eisai
September 5, 2012
- RaQualia to Focus on Fields Where It Can Exhibit Uniqueness, Compile Biz Strategy in November
September 4, 2012
- “Advancements in Domestic Business is Growth Driver” for Achieving Midterm Business Plan : MTPC President Tsuchiya
September 4, 2012
- Ono Ties Up with BioFocus of the UK for Drug Discovery for CNS Disorders
September 4, 2012
- Meiji Seika Pharma Launches COPD Treatment Oxis, Detailed by More Than 600 MRs
September 4, 2012
- Otsuka Applies for Abilify as Adjunctive Therapy for Depression; First Indication for Antipsychotic Drug in Japan
September 4, 2012
- MTPC to Double Number of Vaccine-Specialized MRs to 50, Eyeing TETRABIK Launch
September 3, 2012
- DSP’s US Subsidiary Sunovion to Acquire Elevation Pharmaceuticals of the US
September 3, 2012
- Shionogi to Embark on Collaborative R&D with 5 Danish Universities
September 3, 2012
- MTPC and Nipro Agree on Dissolution of Joint Venture Bipha
September 3, 2012
- 9 Companies Jointly Apply for Combination Use of 3 Agents for H. Pylori Eradication
September 3, 2012
- Wholesalers and Pharmacies See Contrasting Results in 1st Quarter – Which Side Will Come Out the Winner from Non-yieldable Price Bargaining?
September 3, 2012
- Sosei Committed to Becoming a Japan-Based Global Biopharma: Vice President Akihiro Matsuura
September 3, 2012
- Pfizer Japan Launches RCC Treatment Inlyta
August 31, 2012
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…